876710-76-8

Basic information

• Product Name: 5-Fluorobenzimidazole-2-carboxylic acid monohydrate
• Synonyms: 5-Fluorobenzimidazole-2-carboxylic acid monohydrate;6-fluoro-1H-benzimidazole-2-carboxylic acid(SALTDATA: 0.8H2O);6-fluoro-1H-1,3-benzodiazole-2-carboxylic acid;6-fluoro-1H-benzimidazole-2-carboxylic acid;6-fluoro-1H-benzo[d]imidazole-2-carboxylic acid
• CAS NO: 876710-76-8
• Molecular Formula: C8H5FN2O2
• Molecular Weight: 180.14
• Mol File: 876710-76-8.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 447.206°C at 760 mmHg
• Flash Point: 224.263°C
• Appearance: /
• Density: 1.611g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.707
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 5-Fluorobenzimidazole-2-carboxylic acid monohydrate(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Fluorobenzimidazole-2-carboxylic acid monohydrate(876710-76-8)
• EPA Substance Registry System: 5-Fluorobenzimidazole-2-carboxylic acid monohydrate(876710-76-8)

Safety Data

• Hazardous Substances Data: 876710-76-8(Hazardous Substances Data)

Usage

General Description

5-Fluorobenzimidazole-2-carboxylic acid monohydrate is a complex organic compound usually used for advanced chemical research. The name designates its structural features; the benzimidazole core structure comprises a fusion of benzene and imidazole rings, while the '5-Fluoro' suggests a fluorine atom attached at the 5th position of the benzimidazole ring. Its '2-carboxylic acid' functionality suggests a carboxylic group at the 2nd position. Lastly, the 'monohydrate' refers to one molecule of water associated with the compound. It is not typically a naturally occurring substance and requires special synthetic processes for its preparation. Its exact applications can vary widely based on the specific research context.

InChI:InChI=1/C8H5FN2O2/c9-4-1-2-5-6(3-4)11-7(10-5)8(12)13/h1-3H,(H,10,11)(H,12,13)

Upstream product

• 39811-07-9 (5-fluoro-1H-benzimidazole-2-yl)methanol 
• 367-31-7 4-fluoro-1,2-phenylenediamine 
• 673487-34-8 5-fluoro-2-(trichloromethyl)-1H-benzo[d]imidazole 

Relevant articles and documents

Synthesis and evaluation of selected benzimidazole derivatives as potential antimicrobial agents

A library of 53 benzimidazole derivatives, with substituents at positions 1, 2 and 5, were synthesized and screened against a series of reference strains of bacteria and fungi of medical relevance. The SAR analyses of the most promising results showed that the antimicrobial activity of the compounds depended on the substituents attached to the bicyclic heterocycle. In particular, some compounds displayed antibacterial activity against two methicillin-resistant Staphylococcus aureus (MRSA) strains with minimum inhibitory concentrations (MICs) comparable to the widely-used drug ciprofloxacin. The compounds have some common features; three possess 5-halo substituents; two are derivatives of (S)-2-ethanaminebenzimidazole; and the others are derivatives of one 2-(chloromethyl)-1Hbenzo[ d]imidazole and (1H-benzo[d]imidazol-2-yl)methanethiol. The results from the antifungal screening were also very interesting: 23 compounds exhibited potent fungicidal activity against the selected fungal strains. They displayed equivalent or greater potency in their MIC values than amphotericin B. The 5-halobenzimidazole derivatives could be considered promising broad-spectrum antimicrobial candidates that deserve further study for potential therapeutic applications.

CARBAMATE COMPOUND OR SALT THEREOF

[Problems] A compound useful as an active ingredient for a pharmaceutical composition for treating FAAH-related diseases is provided. [Means for Solution] The present inventors have made extensive studies on compounds having an FAAH inhibitory activity, and as a result, have found that a piperazine-1-carboxylate compound, in which benzimidazol-2-ylcarbonyl, benzofuran-2-ylcarbonyl or the like binds to the 4-position of the piperazine, has an excellent FAAH inhibitory activity and further has an action to increase the effective bladder capacity, an action to ameliorate sleep disorders, an anti-diuretic action, and an analgesic activity on lower urinary tract pain including bladder pain and the like, thereby completed the present invention. The carbamate compound of the present invention has an excellent FAAH inhibitory activity and can be used as an agent for preventing and/or treating FAAH-related diseases, particularly nocturia, interstitial cystitis, painful bladder syndrome, or chronic non-bacterial prostatitis/chronic pelvic pain syndrome.